Mirvetuximab soravtansine-gynx beneficial for FRα-positive ovarian cancer, finds phase 3 trial
For sufferers with excessive folate receptor α (FRα)-positive ovarian most cancers, a first-in-class antibody-drug conjugate concentrating on FRα, mirvetuximab soravtansine-gynx ...